Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bolt Biotherapeutics Inc shares valued at $1,594 were purchased by Nemec Sarah on Jun 06 ’24. At $0.64 per share, Nemec Sarah acquired 2,500 shares. The insider’s holdings grew to 13,863 shares worth approximately $4436.16 following the completion of this transaction.
Also, Nemec Sarah purchased 2,500 shares, netting a total of over 1,241 in proceeds. Following the buying of shares at $0.50 each, the insider now holds 16,633 shares.
Before that, Quinn William P. had added 2,500 shares to its account. In a trade valued at $1,594, the President, CEO and CFO bought Bolt Biotherapeutics Inc shares for $0.64 each. Upon closing the transaction, the insider’s holdings increased to 2,500 shares, worth approximately $12407.04.
As published in a research note from Morgan Stanley on January 06, 2022, Bolt Biotherapeutics Inc [BOLT] has been rated down from an Overweight to an Equal-weight. Analysts at SVB Leerink started covering the stock with ‘”an Outperform”‘ outlook in a report released in early March. As of March 02, 2021, Stifel has initiated its “Buy” rating for BOLT. Earlier on March 02, 2021, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for BOLT stock.
Analyzing BOLT Stock Performance
During the last five days, there has been a surge of approximately 7.43%. Over the course of the year, Bolt Biotherapeutics Inc shares have dropped approximately -39.49%. Shares of the company reached a 52-week high of $0.6299 on 01/07/25 and a 52-week low of $0.2810 on 05/29/25.
Support And Resistance Levels for Bolt Biotherapeutics Inc (BOLT)
According to the 24-hour chart, there is a support level at 0.2985, which, if violated, would cause prices to drop to 0.2733. In the upper region, resistance lies at 0.3405. The next price resistance is at 0.3573. RSI (Relative Strength Index) is 47.22 on the 14-day chart, showing neutral technical sentiment.
